retatrutide mechanism of action retatrutide clinical trials 2024 2025 Diagram showing the of Inotropic effects of retatrutide in

These potential benefits, however, come with high costs that raise concerns about the impacts on public and private payers

FDA-approved weight loss medications (semaglutide and tirzepatide) require either a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia

Some like Mounjaro are intended to help individuals manage type 2 diabetes and can only be prescribed as an off-label weight management treatment to patients with chronic conditions

15 Reasons for Caution Not all the data points in the same direction, though

Four individual GLP-1 receptor agonists have now demonstrated MACE superiority in their dedicated cardiovascular outcome trials: Liraglutide: LEADER trial Semaglutide: SUSTAIN-6 and the landmark SELECT trial Dulaglutide: REWIND trial Albiglutide: HARMONY trial The SELECT trial deserves special attention because it broke entirely new ground